Clinical Trial Update: A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial at MD Anderson Cancer Center compares two GVHD prophylaxis regimens after allogeneic stem cell transplantation in acute myeloid leuke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Ruxolitinib (ruxolitinib)
• Sirolimus (Sirolimus)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: AML | Phase 2 | Status: RECRUITING